Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) FCF Margin (2016 - 2025)

Ani Pharmaceuticals' FCF Margin history spans 16 years, with the latest figure at 16.96% for Q4 2025.

  • For Q4 2025, FCF Margin rose 858.0% year-over-year to 16.96%; the TTM value through Dec 2025 reached 20.85%, up 1052.0%, while the annual FY2025 figure was 20.85%, 1052.0% up from the prior year.
  • FCF Margin for Q4 2025 was 16.96% at Ani Pharmaceuticals, up from 13.94% in the prior quarter.
  • Across five years, FCF Margin topped out at 182.59% in Q1 2021 and bottomed at 32.4% in Q1 2022.
  • The 5-year median for FCF Margin is 13.17% (2025), against an average of 15.58%.
  • The largest annual shift saw FCF Margin skyrocketed 18225bps in 2021 before it plummeted -21499bps in 2022.
  • A 5-year view of FCF Margin shows it stood at 20.2% in 2021, then surged by 60bps to 8.0% in 2022, then skyrocketed by 503bps to 32.25% in 2023, then crashed by -74bps to 8.38% in 2024, then surged by 102bps to 16.96% in 2025.
  • Per Business Quant, the three most recent readings for ANIP's FCF Margin are 16.96% (Q4 2025), 13.94% (Q3 2025), and 36.9% (Q2 2025).